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Copyright © 2009 JCBN Summary Oxidative stress (OS) has been implicated as one of the major underlying
mechanisms behind many acute and chronic diseases. However, the measurement of free
radicals or their end products is complicated. Isoprostanes, derived from the non-enzymatic
peroxidation of arachidonic acid are now considered to be reliable biomarkers of oxidant
stress in the human body. Isoprostanes are involved in many of the human diseases such as
type 2 diabetes. In type 2 diabetes elevated levels of F2-Isoprostanes (F2-IsoPs) have been
observed. The measurement of bioactive F2-IsoPs levels offers a unique noninvasive analytical
tool to study the role of free radicals in physiology, oxidative stress-related diseases, and acute
or chronic inflammatory conditions. Measurement of oxidative stress by various other methods
lacks specificity and sensitivity. This review aims to shed light on the implemention of F2-IsoPs
measurement as a gold-standard biomarker of oxidative stress in type 2 diabetics.
Key Words:oxidative stress, lipid peroxidation, isoprostanes, type 2 diabetes
Introduction
“Oxidative stress (OS)” due to the imbalance between
pro-oxidant/antioxidant status results in generation of
reactive oxygen species (ROS) and subsequent modification
of biomolecules such as protein, lipids and nucleic acids.
Excessive generation of ROS has been implicated in a
variety of pathological events such as diabetes, athero-
sclerosis, ischemia-reperfusion injury, cardiovascular disease
and neurodegenerative disease [1]. Lipid peroxidation
(LPO) is the main marker of oxidative stress. Oxidative
damage of cellular membranes has been suggested as a
common mechanism in a large number of biopathological
conditions. It can be measured by either primary or secondary
end products of peroxidation. Primary end products of
lipid peroxidation include conjugated dienes and lipid hydro-
peroxides, while secondary end products include thiobarbi-
turic reactive substances (TBARS), gaseous alkanes and a
group of prostaglandin (PG) F2-like products termed F2-
isoprostanes (F2-IsoPs) [2, 3].
Studies have shown that F2-isoprostanes are reliable
biomarkers of lipid peroxidation [4] and could therefore, be
used as potential indicators of oxidative stress in diverse
conditions. Bioactive F2-isoprostanes (8-Iso-PGF2α) are
regularly formed in various tissues and small amounts can
be found in the unmetabolized form in plasma and higher
levels in urine in normal basal conditions. Their role in the
regulation of normal physiological conditions has yet to be
elucidated. This paper reviews the role of F2-IsoPs as novel
biomarkers of oxidative stress in relation to type 2 diabetes.
Mechanism of F2-IsoPs Formation
IsoPs are a family of PG-like compounds formed non-
enzimatically through free radical catalysed attack on
esterified arachidonate followed by enzymatic release from
cellular or lipoprotein phospholipids (Fig. 1). IsoPs are
formed in situ in the phospholipid domain of cell membranes
and circulating lipoproteins. They are then cleaved byS. Kaviarasan et al.
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phospholipases, released extra-cellularly, circulate in blood
and are excreted in urine. The measurement of F2-IsoPs,
containing the F-type ring analogous to PGF2α, provides a
reliable tool for identifying enhanced rates of lipid peroxida-
tion.
Formation of PG-like compounds during auto-oxidation
of polyunsaturated fatty acids was first reported in the mid-
1970s [5], but isoprostanes were not discovered in humans
until 1990 [6]. F2-isoprostanes are a group of 64 compounds
isomeric in structure to cyclooxygenase-derived PGF2α.
Other products of the isoprostane pathway are also formed
in vivo by rearrangement of labile PGH2-like isoprostane
intermediates. These include E2- and D2-isoprostanes [7],
cyclopentenone-A2- and J2-isoprostanes [8], and the highly
reactive acyclic-ketoaldehydes (isoketals) [9] (Fig. 2).
Biological Effects of F2-IsoPs
The discovery of isoprostanes has important implications
for medicine [7]. It has now been established that measure-
ment of F2-isoprostanes is the most reliable approach to
assess oxidative stress status in vivo, providing an important
tool to explore the role of oxidative stress in the patho-
genesis of human disease. In addition, products of the iso-
prostane pathway have been found to exert potent biological
actions and therefore may be pathophysiologic mediators of
disease. IsoPs 8-iso-PGF2α and 8-iso-PGE2 possess potent
biological effects in various systems and they also serve as
mediators of oxidant stress through their vasoconstrictive
[10] and inflammatory properties. 8-iso-PGF2α, have been
well known to have vasoconstictive effects in various organs
including aorta [11], brain [12], cerebral arterioles [13],
kidney [6,  10], the lung [14,  15], pulmonary artery [6],
retinal vessels and endothelium [16]. Administration of 8-
iso-PGF2α to rabbit induces COX-mediated PGF2α formation
which has shown to be related to inflammation [17, 18].
Isoprostanes induces inflammation and atherogenesis
through activation of MAP kinases [19]. Isoprostanes
possess important in vitro activities that could be relevant to
the pathophysiology of atherosclerosis. It promotes platelet
activation [20] and induces mitogenesis in vascular smooth
muscle cells [10], stimulates proliferative responses in
fibroblasts [21], alters endothelial cell biology as indicated
by proliferative effects and increased endothelin-1 expres-
sion in bovine aortic endothelial cells [22]. A simplified
schematic sketch about its biological effects is shown in
Fig. 3.
Fig. 1. Formation of F2-Isoprostanes from arachidonic acid, leading to four F2-Isoprostane regioisomers (Adapted from ref. 54)F2-Isoprostanes as Novel Biomarkers
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Mechanism of Action of F2-IsoPs
Biological effects of IsoPs are mediated by interaction
with receptor. The cyclopentenone-IsoPs such as PGA2 and
PGJ2 like compounds, form protein adduct by reacting with
glutathione [8]. Isoketals, the byproducts of IsoPs pathway
rapidly adduct to lysine residues on proteins and induce
cross-linkages [9]. It’s still uncertain about the receptors
involved in IsoPs actions. The vasoconstricting action is
mediated through thromboxane (Tx) receptor antagonists
[23]. It acts as antagonist in Tx induced platelet aggregation
[24] and induces vasoconstriction in retinal and brain
vasculature by endothelial Tx formation [25].
Metabolism of IsoPs
IsoPs are produced in situ in their esterified form in
tissues and bioconvert first to their free acid form (Fig. 4)
and are distributed in both the esterified and free acid form
in tissues [26, 27]. Hydrolytic enzymes that are ubiquitous
in the body are primarily responsible for the formation of
free isoprostanes from their esterified moiety in the tissues
and these are released into the circulation. Pharmacokinetic
and metabolic studies revealed the half life of 8-iso-PGF2α
to be ~16 min in humans and ~4 min in plasma. In vitro
and in vivo studies showed that the metabolism of IsoPs
occurs through prostaglandins [28, 29] and confirms that β-
oxidation is the common degradation pathway in the later
step of metabolism of IsoPs.
Biomarkers of LPO and OS
Oxidation of polyunsaturated fatty acids (PUFA) by free
radicals results in excess production of toxic byproducts of
peroxidation [30], which is the major underlying mechanism
of development of various diseases such as cancer, cardio-
Fig. 2. Tx: thromboxane. IsoK: isoketals (Adapted from ref. 55)
Fig. 3. A simplified sketch showing biological effects of F2-
IsoprostanesS. Kaviarasan et al.
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vascular and neurological diseases [1]. There exists a lack of
reliable analytical methods for detection of peroxidation
in vivo or its end products [2]. A number of studies have
revealed the favorable properties of F2-IsoPs as biomarkers
for peroxidation and its levels are regarded as the reliable
approach for the assessment of peroxidation or OS in vivo
[6, 31, 32, 33, 34]. The schematic diagram of the formation
of 8-Iso-PGF2α, a major F2-IsoPs from arachidonic acid is
shown in Fig. 5.
IsoPs in Type 2 Diabetes
OS is implicated in the development of diabetic complica-
tions [35] by its association with peroxidation of membrane
lipids and LDL-cholesterol. These peroxidation products
can impair beta cell function and induce apoptosis [36].
Factors that promote increased oxidative stress in diabetes
include antioxidant deficiencies, increased production of
ROS, and the process of glycation and glyco-oxidation [35].
The most common antioxidant deficiencies reported in
diabetes are lower levels of ascorbate, glutathione and
superoxide dismutase [37]. Lower concentrations of reduced
glutathione have been documented in diabetic neutrophils
and monocytes while lower concentrations of ascorbate have
been found in both diabetic plasma and mononuclear cells.
Direct evidence of increased oxidative stress and lipid
peroxidation in diabetes has been reported. F2-IsoPs are
prostaglandin-like compounds formed in-vivo from free
radical catalyzed peroxidation of arachidonic acid and have
emerged as novel and direct measures of oxidative stress.
IsoPs, derived from the non-enzymatic peroxidation of
arachidonic acid are associated with hyperglycemia, vaso-
constriction and diabetic nephropathy [38, 39]. F2-Isops, in
urine or plasma, provide a highly precise and reliable
approach to assess lipid peroxidation in vivo [31]. F2-IsoPs
have been found to be increased in both type I and type II
diabetes [40]. Increased isoprostane levels were observed
in plasma and urine of type 2 diabetes (NIDDM) [40, 38].
Gopaul et al. [40] have reported that 8-iso-PGF2α (a major
F2-IsoPs) was found to be threefold higher in type 2
Fig. 4. Formation of free F2-Isops from the esterified moiety (Adapted from ref. 56)
Fig. 5. Biosynthesis of 8-Iso-PGF2α (F2-IsoPs) (Adapted from
ref. 34)F2-Isoprostanes as Novel Biomarkers
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diabetics than in healthy individuals. In addition, increased
urinary excretion of 8-iso-PGF2α was statistically significant
in patients with diabetic ketoacidosis [41]. There exists a
significant correlation between blood glucose and urinary
IsoPs levels, suggesting that peroxidation is related to
glycemic control. In vascular smooth muscle cells, F2-IsoPs
formation was found to be induced by in vitro by high
glucose concentrations [42]. Further, the suggestion that
impaired glycemic control is responsible for enhanced
formation of F2-IsoPs in type II disease is also supported
by the finding that intensive antidiabetic treatment resulted
in reductions in blood glucose levels and in urinary IsoP
levels [38]. Improved metabolic control of type 2 diabetic
patients significantly reduced urinary 8-iso-PGF2α levels by
32%. Furthermore improved glycemic control by pancreatic
islet transplantation reduces vascular oxidative stress and
reverses antioxidant enzyme upregulation in rats with
streptozotocin-induced diabetes are consistent with hyper-
glycemia as the source of oxidative stress [42].
Hyperglycemia, a major common feature of diabetes has
been implicated as the source of metabolic derangement.
Increase in 8-iso-PGF2α was significantly correlated with
blood glucose and increased platelet activation. Activation
of platelets by hyperglycemia paralleled oxidative stress
[43]. These results strongly suggest that increased lipid
peroxidation in diabetic patient’s leads to the formation of
8-iso-PGF2α, which, in turn, leads to platelet activation. This
is of interest because F2-IsoPs are ligands for the TPx
receptor [44]. In another study, levels of esterified. F2-IsoPs
in plasma lipids were quantified in 61 patients who under-
went coronary angiography. The extent of coronary athero-
sclerosis in the diabetic patients was similar to that in the 46
nondiabetic individuals. Plasma levels of F2-IsoPs measured
in the diabetic patients (33.4 ± 4.8 pg/mL, mean ± SEM)
were found to be significantly increased compared with levels
measured in the nondiabetic patients (22.2 ± 1.9 pg/mL)
(p<0.02). Plasma F2-IsoP concentrations were found to be
increased by 34% in acute hyperglycemia and this is similar
to other models of oxidative damage. Increased plasma
esterified 8-epi-F2α-IsoPs were reported in heavy smokers
by Morrow et al. [45]. 8-epi-F2α-IsoPs possess biologically
important proatherogenic actions, and serves as well as a
marker for free radical damage. Under in vitro condition it
promotes platelet adhesion to collagen and antagonizes the
action of nitric oxide.
Laight et al. [46] recently reported a 5 fold increase in
plasma 8-iso-PGF2α, in the obese Zucker rat, a model of
insulin resistance. Supplementation of vitamin-E reduced
plasma 8-iso-PGF2α and reversed hyperinsulinemia. Alpha
tocopherol therapy significantly decreased oxidative suscepti-
bility of LDL as manifest by prolongation of the lag phase.
In both diabetic groups with and without vascular complica-
tions the O2− anion release was increased and that this could
be attenuated with high dosage alpha tocopherol therapy
(1200 IU/RRR-AT). Furthermore, alpha tocopherol therapy
resulted in a reduction in IL1-β, TNF-α, IL-6 and C-reactive
protein in the diabetic group.
Hyperglycemia contributes significantly to microvascular
disease. The combination of insulin resistance, dyslipidemia,
and hypertension contributes to cardiovascular disease
(CVD) risk even before glucose intolerance develops. High
plasma levels of homocysteine are an independent risk
factor for cardiovascular disease [47]. The mechanism by
which hyperhomocysteinemia induces atherosclerosis is not
fully understood but promotion of LDL oxidation has been
suggested. The relationship between total plasma concentra-
tions of homocysteine and F2-IsoPs has been explored [48].
Plasma concentrations of F2-IsoPs increased linearly across
quintiles of homocysteine levels. The simple correlation
coefficient for association between plasma concentrations
of homocysteine and F2-IsoPs was 0.40 (p<0.0001). The
finding of a positive correlation between plasma concentra-
tions of F2-IsoPs and homocysteine supports the suggestion
that the underlying the link between high homocysteine
levels and risk for cardiovascular disease may be enhanced
lipid peroxidation.
In accordance with the LDL oxidation hypothesis of
atherosclerosis, levels of F2-IsoPs should be higher in
atherosclerotic plaques than in normal vascular tissue. To
address this issue, levels of F2-IsoPs were measured in
fresh advanced atherosclerotic plaque tissue removed during
arterial thrombarterectomy (n = 10) and compared with levels
measured in normal human umbilical veins removed from
the placenta immediately after delivery (n = 10) [49]. Levels
of esterified F2-IsoPs in vascular tissue normalized to both
wet weight and dry weight were significantly higher in
atherosclerotic plaques compared to normal vascular tissue.
A better measure of the actual extent of oxidation, however,
may be obtained by normalizing the data to the amount of
arachidonic acid present in the tissue since it is the substrate
for IsoP formation. When the data was normalized to
arachidonic acid content, the F2-IsoP/arachidonic acid ratio
was ~4-fold higher in diseased tissue than the ratio in normal
vascular tissue (p = 0.009). This finding indicates that
unsaturated fatty acids in atherosclerotic plaques are more
extensively oxidized than lipids in normal vascular tissue.
These observations are also in accord with data from
FitzGerald and colleagues who have shown increased
amounts of F2-IsoPs in human atherosclerotic lesions and
the localization of F2-IsoPs in atherosclerotic plaque tissue
to foam cells and vascular smooth muscle cells [50]. While
8-iso-PGF2α, plays a pivotal role in patients with insulin
resistance and hyperglycemia its role is still unclear in
subjects without evident hyperglycemia.S. Kaviarasan et al.
J. Clin. Biochem. Nutr.
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Comprehensive Treatment
Diabetes-related complications may be limited with much
better glycemic control. Good glycemic control can reduce
microvascular complications of the eyes, kidneys, and
nerves. CVD is the most common and clinically important
secondary complication in adults with diabetes [51]. CVD
affects up to 80% of those with diabetes and accounts for
approximately 70% of mortality in diabetes patients.
Diabetes increases the risk of CVD 2 to 4 times [52], and the
risk is greatest for women [53]. Data suggest that individuals
with diabetes have a risk of CVD events that is comparable
with that of individuals without diabetes who have pre-
existing CVD. Abnormalities in blood pressure or lipids
will have a greater negative impact on diabetic patients
than on those without diabetes. Type 2 diabetes should not
be regarded simply as a metabolic syndrome, but as a
vascular syndrome with metabolic consequences, including
hyperglycemia and insulin resistance. Indeed, type 2 diabetes
generally arises in the same metabolic setting as CVD.
Obesity, hypertension, dyslipidemia, and insulin resistance
are common to both conditions. This fact and the presence of
modifiable risk factors in patients with diabetes suggest that
early and aggressive treatment can significantly reduce the
risk of heart disease hence the requirement for good markers
for this disease and its complications.
Conclusion
OS is the major pathogenic origin for acute and chronic
diseases. Available biomarkers for OS are unreliable for
assessing the oxidative damage in vivo which results in
substandard interpretation of role of OS in various diseases.
Current evidences presented above in the review unveil the
possibility and reliability of IsoPs as valid biomarkers for
the evaluation of OS. Being a bioactive compound it is
involved in the normal physiology such as human pregnancy
and in the pathology of inflammation. This should help us to
explore the role of free radicals in the pathogenesis of human
diseases. Further research in this area is necessary to provide
insight into the role of OS in human diseases.
Abbreviations
OS, oxidative stress; LPO, lipid peroxidation; IsoPs,
Isoprostanes; ROS, reactive oxygen species; TBARS,
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